Central retinal thickness at 3 months after surgery; · people with diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Quality of life measures · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
Laser photocoagulation probably leads to lower worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines… compared with no intervention (moderate certainty).
1 finding from 1 review
RR 0.42 [0.2, 0.9]
Studies not reported
Moderate
Visual acuity · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anatomic measures: partial to complete resolution of the macular oedema with stereoscopic fundus photography or biomicroscopy; leakage on fluorescein angiography (IVFA); and, if available, retinal macular thickness with OCT · people with diabetic macular oedema
Laser photocoagulation probably leads to higher anatomic measures: partial to complete resolution of the macular… compared with no intervention (moderate certainty).
1 finding from 1 review
RR 1.55 [1.3, 1.86]
Studies not reported
Moderate
Central retinal thickness at 3 months after surgery; · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measures · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
It is very uncertain whether subthreshold changes improvement of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS… compared with standard macular photocoagulation (very low certainty).
1 finding from 1 review
RR 0.31 [0.01, 7.09]
Studies not reported
Very low
Worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines or 0.3 logMAR · people with diabetic macular oedema
It is very uncertain whether subthreshold changes worsening of BCVA defined as ≥ 15 ETDRS letters (i.e. 3 ETDRS lines… compared with standard macular photocoagulation (very low certainty).
1 finding from 1 review
RR 0.93 [0.15, 5.76]
Studies not reported
Very low
Improvement in ocular motility (ocular alignment ≤ 10 prism dioptres). · people with sixth nerve palsy
Botulinum toxin showed no clear difference in improvement in ocular motility (ocular alignment ≤ 10 prism dioptres). compared with observation (low certainty).
1 finding from 1 review
Secondary outcome: achievement of binocular single vision · people with sixth nerve palsy
Botulinum toxin showed no clear difference in achievement of binocular single vision (fusion and stereopsis… compared with observation (low certainty).
1 finding from 1 review
Improvement in functional ability · people with sixth nerve palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with sixth nerve palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events. · people with sixth nerve palsy
1 finding from 1 review
Intervention not reported
Gabapentin up to 900 mg/day) versus baclofen (up to 30 mg/day). · people with acquired nystagmus
1 finding from 1 review
Intervention not reported
3,4‐DAP (20 mg, single dose) versus placebo. Assessments made 30 minutes after taking the drug or placebo · people with acquired nystagmus
1 finding from 1 review
Intervention not reported
4‐AP (10 mg, single dose) versus 3,4‐DAP (10 mg, single dose) Assessments made at 45 and 90 minutes after taking the drug · people with acquired nystagmus
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with centre‐involving diabetic macular oedema
1 finding from 1 review
no estimate extracted
Studies not reported
Low